Akari Therapeutics, Plc (AKTX)

1.4700 -0.3000 (-16.95%) 收市：04:00PM EDT

Akari Therapeutics, Plc

22 Boston Wharf Road
Floor 7
Boston, MA 02210
United States
929 274 7510
https://www.akaritx.com

版塊: Healthcare
行業: Biotechnology
全職員工: 9

高階主管

名稱	頭銜	支付	行使價	出生年份
Ms. Rachelle Suzanne Jacques	President, CEO & Director	632.25k	無	1971
Ms. Melissa Bradford-Klug	Chief Operating Officer	無	無	1970
Dr. Miles Nunn	Chief Scientific Officer	無	無	1969
Dr. John F. Neylan III, M.D.	Executive VP & Chief Medical Officer	無	無	1953

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.

公司管治

截至 無 止，Akari Therapeutics, Plc 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。